Discovery inhibitor

Manufactured by Roche

The Discovery inhibitor is a laboratory instrument designed for the identification and characterization of small molecule inhibitors. It facilitates the screening and evaluation of candidate compounds to support drug discovery research.

Automatically generated - may contain errors

Lab products found in correlation

Ab27588, by Abcam (1 mentions) Omnimap goat anti rabbit hrp, by Roche (1 mentions) 3 3 diaminobenzidine (dab), by Roche (1 mentions) Hematoxylin 2, by Roche (1 mentions) Ventana discovery ultra, by Roche (1 mentions) Dna dye dapi, by Thermo Fisher Scientific (1 mentions) Tissuefaxs 200 system, by TissueGnostics (1 mentions) α sma, by Abcam (1 mentions) Anti ccl19, by R&D Systems (1 mentions) Anti cxcl13, by Abcam (1 mentions) Discovery ultra, by Roche (1 mentions) Anti cd45, by BD (1 mentions)

4 protocols using discovery inhibitor

Automated Immunohistochemical Analysis of B2M and Melanoma Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Procedures were done on the automated Ventana Discovery Ultra
staining system, using 4μm formalin-fixed paraffin-embedded sections.
Sections were deparaffinized in xylene and graded alcohols, followed by
antigen retrieval (EDTA), blocking with Discovery inhibitor (Ventana;
760–4840), incubation with primary antibodies for 16 minutes, washing
and incubation with a secondary antibody conjugated with horseradish
peroxidase (HRP). Sections were developed with discovery purple chromogen
kit (Ventana; 760–229) and were then counterstained with hematoxylin.
Primary antibodies used were: B2M (Abcam; ab27588; 1:1000); anti melanoma
triple cocktail (Ventana; 790–4677; 1:100) containing antibodies
against melanosome (HMB45), Mart-1/melan A (A103), tyrosinase (T311). The
melanoma triple cocktail was used to separate tumor from normal cells
enabling detection of B2M in the cancerous cell fraction.

Sade-Feldman M., Yizhak K., Bjorgaard S.L., Ray J.P., de Boer C.G., Jenkins R.W., Lieb D.J., Chen J.H., Frederick D.T., Barzily-Rokni M., Freeman S.S., Reuben A., Hoover P.J., Villani A.C., Ivanova E., Portell A., Lizotte P.H., Aref A.R., Eliane J.P., Hammond M.R., Vitzthum H., Blackmon S.M., Li B., Gopalakrishnan V., Reddy S.M., Cooper Z.A., Paweletz C.P., Barbie D.A., Stemmer-Rachamimov A., Flaherty K.T., Wargo J.A., Boland G.M., Sullivan R.J., Getz G, & Hacohen N. (2018). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell, 175(4), 998-1013.e20.

+ Open protocol

+ Expand

Multiplex Immunohistochemistry for Mast Cells and Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tryptase was used to detect MCs; CD34 staining, an endothelial cell marker, was used to visualize the glomerular and tubular interstitial compartments. The corresponding second section of each biopsy was stained by chromogenic multiplex staining: briefly, after de-paraffinization, CC1 (#950-124; Ventana Medical Systems, Tucson, AZ) antigen retrieval was performed for 64 min at 95°C, followed by incubation for 8 min with the Discovery inhibitor (#760-4840; Ventana Medical Systems). Primary antibody CD34 (#790-2927; Ventana Medical Systems) was incubated for 32 min at 37°C, followed by detection with OmniMap goat-anti-rabbit HRP (#760-4311; Ventana Medical Systems), and visualized using purple kit for 32 min. A CC2 (#950-123, Ventana Medical Systems) 100°C stripping step was performed for 8 min. Tryptase (#760-4276; Ventana Medical Systems) was incubated at 37°C for 32 min, followed by secondary antibody, OmniMap goat-anti-mouse HRP (#760-4310; Ventana Medical Systems) at 37°C for 24 min, and visualized with 3,3′-Diaminobenzidine (#760-229; Ventana Medical Systems) for 32 min. Finally, Hematoxylin II (#790-2208; Ventana Medical Systems) was used to counter stain for 8 min and then a blue coloring reagent (#760-2037; Ventana Medical Systems) for 4 min according to the manufactures instructions (Ventana Medical Systems).

Varol H., van der Elst G., Baan C.C., van Baardwijk M., Hesselink D.A., Duong van Huyen J.P., Kramann R., Rabant M., van den Bosch T.P, & Clahsen-van Groningen M.C. (2023). Mast Cells in Kidney Transplant Biopsies With Borderline T Cell-mediated Rejection and Their Relation to Chronicity. Transplantation Direct, 9(5), e1480.

+ Open protocol

+ Expand

Quantitative Immunofluorescence Imaging of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patient prostate tissues or mouse tumors were fixed in 10% formalin in PBS and embedded in paraffin. 4μm sections were baked at 60°C for 1 hr and subjected to Immunofluorescence staining using the Ventana Discovery Ultra autostainer with buffers and antibodies from Ventana Medical Systems (Oro Valley, AZ). Briefly slides were deparaffinized using EZ solution, followed by antigen retrieval with Cell Conditioning 1 (CC1) solution (prediluted Tris solution, pH 8.0) for 64 min at 95°C and blocking with Discovery inhibitor (Ventana) for 12 min at RT. The slides were incubated with αCD8 (Ventana) or αKi-67 (Ventana) at 37°C for 28 minutes followed by detection with anti-rabbit-HQ/ αHQ-HRP/ DAB (Ventana) or Red610 kits (Ventana). DNA dye DAPI (Invitrogen) was used to stain the nucleus. Slides was scanned using TissueFAXS 200 system (TissueGnostics, Tarzana, CA). Image was analyzed using QuPath (Edinburgh, UK) with default settings. For all summarized data, 3 random high-power fields were evaluated by automated image analysis and averaged prior to generating a mean for each experimental group.

Wang Y., You S., Su S., Yeon A., Lo E.M., Kim S., Mohler J.L., Freeman M.R, & Kim H.L. (2021). Cholesterol-lowering Intervention Decreases mTOR Complex 2 Signaling and Enhances Antitumor Immunity. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(2), 414-424.

+ Open protocol

+ Expand

Immunohistochemistry Staining of Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry staining was performed on 4μm formalin-fixed paraffin-embedded sections. MC38 tumor staining was performed as previously described (59 (link)) using anti-CD45 (BD Bioscience, 550539) and anti-CD8 (Synaptic System, 361 003) antibodies employing a citrate buffer pressure cooker for antigen retrieval. For human tumor staining, all procedures were done on the automated Ventana Discovery Ultra staining system. Sections were first deparaffinized using EZ prep solution and antigen retrieval was achieved using Cell Conditioning solution 1. Sections were blocked with Discovery Inhibitor (all from Ventana). Sections were incubated with primary antibodies for 16 minutes for population markers and 12 hours for CXCL13 and CCL19 then washed and incubated with OmniMap anti-Mouse or anti-Rabbit conjugated with horseradish peroxidase (HRP) (Ventana, cat# 760-4310 and 760-4311) for additional 16 minutes. Discovery Purple or OmiMAP DAB chromogen kits (cat# 760-229 or 760-159) was then applied to generate a color reaction. Slides were then counterstained with hematoxylin II followed by bluing reagent (Ventana, cat# 790-2208 and cat# 760-2037). Primary antibodies used for staining were: anti-CCL19 (RD Systems, cat# MAB361-100; 1:200) and anti-CXCL13 (Abcam, cat# ab112521; 1:150), CD31 (Cell Marque, cat# 131M-94; 1:500); αSMA (Abcam, cat# ab5694; 1:400).

Jenkins R.W., Aref A.R., Lizotte P.H., Ivanova E., Stinson S., Zhou C.W., Bowden M., Deng J., Liu H., Miao D., He M.X., Walker W., Zhang G., Tian T., Cheng C., Wei Z., Palakurthi S., Bittinger M., Vitzthum H., Kim J.W., Merlino A., Quinn M., Venkataramani C., Kaplan J.A., Portell A., Gokhale P.C., Phillips B., Smart A., Rotem A., Jones R.E., Keogh L., Anguiano M., Stapleton L., Jia Z., Barzily-Rokni M., Cañadas I., Thai T.C., Hammond M.R., Vlahos R., Wang E.S., Zhang H., Li S., Hanna G.J., Huang W., Hoang M.P., Piris A., Eliane J.P., Stemmer-Rachamimov A.O., Cameron L., Su M.J., Shah P., Izar B., Thakuria M., LeBoeuf N.R., Rabinowits G., Gunda V., Parangi S., Cleary J.M., Miller B.C., Kitajima S., Thummalapalli R., Miao B., Barbie T.U., Sivathanu V., Wong J., Richards W.G., Bueno R., Yoon C.H., Miret J., Herlyn M., Garraway L.A., Van Allen E.M., Freeman G.J., Kirschmeier P.T., Lorch J.H., Ott P.A., Hodi F.S., Flaherty K.T., Kamm R.D., Boland G.M., Wong K.K., Dornan D., Paweletz C.P, & Barbie D.A. (2017). Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer discovery, 8(2), 196-215.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!